Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 13/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30222457 | 0.91 | CCR2 (0.33) | CCR2NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL29678643 | 0.91 | CCR2 (0.33) | CCR2NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL30403301 | 0.79 | L3MBTL1 (0.38) | CCR2L3MBTL1HTTCCR1CCR5 | |
| SCHEMBL29015392 | 0.77 | FOLH1 (0.51) | CCR2L3MBTL1HTT | |
| SCHEMBL29015390 | 0.77 | FOLH1 (0.51) | CCR2L3MBTL1HTT | |
| SCHEMBL7351109 | 0.75 | L3MBTL1 (0.40) | CCR2L3MBTL1HTTCCR1CCR5 | |
| SCHEMBL30402698 | 0.75 | CCR2 (0.40) | CCR2L3MBTL1 | |
| SCHEMBL30140717 | 0.74 | L3MBTL1 (0.39) | CCR2L3MBTL1HTT | |
| SCHEMBL30403414 | 0.71 | L3MBTL1 (0.39) | CCR2L3MBTL1HTT | |
| SCHEMBL30174805 | 0.70 | KDM4E (0.36) | CCR2L3MBTL1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4165037-A1 | ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS | Aligos Therapeutics, Inc. (US) | 2023-04-19 | — | — | EP | disclosed |